NanoPhoria Bioscience

Biotech · Milan, IT

Biotech with a nano-in-micro delivery platform based on calcium phosphate nanoparticles for heart failure.

Founders

Daniele Catalucci (Italy · ♂) — A CNR cardiac researcher, he co-founded NanoPhoria in 2022 as a spin-off to commercialize a calcium-phosphate nano-in-micro delivery platform for a first-in-class heart-failure therapy.
Michele Iafisco (Italy · ♂) — A CNR materials/nanoparticle scientist, he co-founded NanoPhoria in 2022 to develop inorganic calcium-phosphate nanocarriers for delivering therapeutic peptides and RNA.
Alessio Alogna (Italy · ♂) — He co-founded NanoPhoria in 2022, contributing to the CNR spin-off building a tissue-directed lung-to-heart nanoparticle drug-delivery platform.
Claudio De Luca (Italy · ♂) — He co-founded NanoPhoria in 2022 as part of the team commercializing CNR's non-viral nano-in-micro delivery technology for heart failure.

Shares the most investors with (number = shared investors):

Date	Round	Amount
Oct 2025	Series A NanoPhoria closed an €83.5 million Series A led by XGEN Venture, Sofinnova Partners and CDP Venture Capital, the largest Italian biotech Series A.	$96.9M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.